Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

Breast Cancer

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

Eur J Cancer

Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L

doi: 10.1016/j.ejca.2024.115108

SABCS 2024

Breast Cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

SABCS 2024

Breast Cancer

Updates on ADCs in treatment of advanced breast cancer

CHICAGO 2025

Breast Cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

Gynecologic Cancer

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Ann Oncol

Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ, Leiva M, Cetina-Pérez LDC, Varga S, Molina Alavez A, Alarcon-Rozas AE, Valdiviezo N, Acevedo C, Figueroa A, Santini A, Vera L, Rey F, Kahán Z, Galaz P, Meléndez Mier G, Wu X, Mandai M, Shapira-Frommer R, Estevez-Diz MDP, Limaye S, Xin W, Dry H, Broggi MAS, Yuan DY, Stewart RA, Monk BJ

doi: 10.1016/j.annonc.2025.05.533

Breast Cancer

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study

Eur J Cancer

Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E

doi: 10.1016/j.ejca.2024.115219

CHICAGO 2025

Breast Cancer

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer

Related content

Advancing Breast Cancer Treatment with Elacestrant

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

Updates on ADCs in treatment of advanced breast cancer

LBA4: SERENA-6: Switching to camizestrant plus CDK4/6 inhibitor significantly delays progression in HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation in first line

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study

INAVO120: Inavolisib significantly improves OS when added to palbociclib and fulvestrant in patients with PIK3CA-mutated HR-positive, HER2-negative endocrine-resistant advanced breast cancer